Skip to content
Home/Companies/Biotech/The Native Antigen Company
The Native Antigen Company

The Native Antigen Company

Biotech·UK·Exited 2020·Held 6yr
Entry
2014
Hold
6yr
Exit
2020

Who owns The Native Antigen Company?

The Native Antigen Company was owned by Mercia Asset Management through Mercia Direct Investments (2014 vintage) from 2014 to 2020, exited via Trade Sale.

Buyer identity and MOIC available on Pro.

Hand-verified · updated 2026-06-01

Mercia Asset Management
Investor
Mercia Asset Management
Mercia Direct Investments · 2014 · Balance Sheet

Key facts

HQUK
SectorBiotech
StatusAcquired
Websitethenativeantigencompany.com
Exit Type
Trade Sale
Buyer
MOIC
Exit Year
2020

More from Mercia Direct Investments

Other portfolio companies in the same fund.

sureCore
sureCore
Exited 2026
Deep TechUK
Aonic
Aonic
Active
SoftwareSweden· 2023
Axis Spine Technologies
Axis Spine Technologies
Active
MedTechUK· 2022
Netacea
Netacea
Active
CybersecurityUK· 2022
Nova Pangaea
Nova Pangaea
Active
ClimateTechUK· 2022
Forensic Analytics
Active
SoftwareUK· 2021

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track The Native Antigen Company

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on The Native Antigen Company.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue